Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs

Journal of the American Animal Hospital Association

Volumn 42, Issue 4, 2006, Pages 249-261

  Lombard, Christophe W ^a   Jöns, Olaf ^c   Bussadori, Claudio M ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Clinica Veterinaria Gran Sasso   (Italy)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; AMLODIPINE; BENAZEPRIL; CARVEDILOL; DEXTROMETHORPHAN; DIGOXIN; FUROSEMIDE; HYDRALAZINE; PIMOBENDAN; PLACEBO; SPIRONOLACTONE; TERBUTALINE;

ARTICLE; CONTROLLED STUDY; COUGHING; DEATH; DOG DISEASE; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; LONG TERM CARE; LUNG EDEMA; MALE; NONHUMAN; RANDOMIZATION; SCORING SYSTEM; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT FAILURE; TRICUSPID VALVE DISEASE;

CANIS FAMILIARIS;

EID: 33746161914     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0420249     Document Type: Article

References (35)

1. Ettinger SJ. Valvular heart disease. In: Ettinger SJ, ed. Textbook of Veterinary Internal Medicine. Diseases of the Dog and Cat. 3rd ed. Philadelphia: WB Saunders, 1989:1031-1050.
2. Sisson D. Acquired valvular heart disease in dogs and cats. In: Bonagura JW, ed. Contemporary Issues in Small Animal Practice: Cardiology. New York. Churchill Livingstone, 1987:59-116.
3. Buchanan JW. Chronic valvular heart disease (endocardiosis) in dogs. Adv Vet Sci Comp Med 1977;21:75-106.
4. Carabello BA. The pathophysiology of mitral regurgitation. J Heart Valve Dis 2000;9:60,0-608.
5. Häggström J, Hansson K, Karlberg BE, et al. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996;57:1645-1652.
6. The IMPROVE Study Group. Acute and short-term hemodynamics, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the invasive multicenter prospective veterinary evaluation of enalapril study. J Vet Intern Med 1995;9:234-242.
7. The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the cooperative veterinary enalapril study group. J Vet Intern Med 1995;9:243-252.
8. Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc 1998;213:1573-1577.
9. Kvart C, Häggström J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:80-88.
10. Atkins CE. Enalapril monotherapy in asymptomatic mitral regurgitation: Result of VETPROOF (Veterinary Enalapril Trial to Prove Reduction in Onset of Failure). In: Proceed Am Coll Vet Intern Med Forum, Dallas 2002;20:75-76.
11. Dell'Italia LJ, Balcells E, Meng QC, et al. Volume-overload hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol 1997;273:H961-H970.
12. Dell'Italia LJ. The renin-angiotensin system in mitral regurgitation: a typical case of tissue activation. Curr Cardiol Rep 2002;4:97-103.
13. Lord P, Eriksson A, Häggström J, et al. Increased pulmonary transit times in asymptomatic dogs with mitral regurgitation. J Vet Intern Med 2003;17:824-829.
14. Van Meel JCA, Dierden W. Hermodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989;14(Suppl 2):S1-S6.
15. ++ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1988; 63:911-922.
16. Pouleur H, Hanet C, Schroder E, et al. Effects of pimobendan (UDCG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. J Cardiovasc Pharmacol 1989; 14(Suppl 2):SI8-S22.
17. Hagemeijer F. Calcium sensitization with pimobendan; pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Euro Heart J 1993;14:551-566.
18. Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986; 126: 20-21.
19. Sasaki T, Kubo T, Komamura K, et al. Effect of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. J Cardiol 1999;33:317-325.
20. Erlemeier HH, Kupper W, Bleifield W. Comparison of hormonal and hemodynamic changes after long-term therapy with pimobendan or enalapril - a double-blind randomised study. Euro Heart J 1991;12:889-899.
21. Baumann G, Ningel K, Permanetter B. Cardiovascular profile of UD-CG 115BS - pimobendan and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 1989;13:730-738.
22. Asanoi H, Ishizaka S, Kameyama T, et al. Disparate inotropic and lusitropic response to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 1994;23:268-274.
23. Bastida E, Escolar G, Rodriguez-Gomez J, et al. UD-CG 115, a benzimidazole-pyridazinone compound with cardiovascular activity inhibits platelet thrombus formation. Abstract Thrombosis Res 1986;42(Suppl 6):145.
24. Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol 1999;33:1400-1407.
25. Fuentes VL, Corcoran B, French A, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 2002;16:255-261.
26. O'Grady MR. Minors SL, O'Sullivan LM, et al. Evaluation of the efficacy of pirnobendan to reduce mortality and morbidity in Doberman pinchers with congestive heart fadure due to dilated cardiomyopathy (abstract). In: Proceed Am Coll Vet Intern Med Forum, Charlotte 2003;21:1011.
27. The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild-to-moderate heart failure - the effects of pimobendan on chronic heart failure study. Circ J 2002;66:149-157.
28. Smith PJ, French AT, Van Israel NV, et al. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005;46:121-130.
29. Lombard CW. Pimobendan in congestive heart failure. In: Proceed Am Coll Vet Intern Med Forum, Charlotte 2003;21:104.
30. Lombard CW. Pimobendan in mitral regurgitation vs dilated cardiomyopathy. In: Proceed Am Coll Vet Intern Med Forum, Minneapolis 2004;22:97-98.
31. Gordon SG. Pimobendan and chronic valvular disease: a retrospective study. In: Proceed Am Coll Vet Intern Med Forum, Minneapolis 2004;22:99.
32. International Small Animal Cardiac Health Council. Appendix 1: Recommendations for the diagnosis of heart disease and treatment of heart failure in small animals. In: Tilley LP, Goodwin JP, eds. Manual of Canine and Feline Cardiology. 3rd ed. Philadelphia: WB Saunders, 2001:459-489.
33. Buchanan JW, Bucheler J. Vertebral scale system for cardiac mensuration. J Am Vet Med Assoc 1995;206:194-199.
34. The BENCH (Benazepril Hydrochloride in Canine Heart Disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, longterm clinical trial. J Vet Cardiol 2004;6:7-18.
35. O'Grady MR, Minors SL, O'Sullivan ML, et al. Assessment of the ability of pimobendan to increase the frequency of ventricular ectopy in dogs with congestive heart failure due to dilated cardiomyopathy or mitral valve insufficiency (abstract). In: Proceed Am Coll Vet Intern Med Forum, Minneapolis 2004;22:877.